Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.

Journal Article

PURPOSE: Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied. METHODS: Eight dosages of MTX 7.5 mg/m2 every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued. RESULTS: The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable. CONCLUSION: Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.

Full Text

Duke Authors

Cited Authors

  • Mulne, AF; Ducore, JM; Elterman, RD; Friedman, HS; Krischer, JP; Kun, LE; Shuster, JJ; Kadota, RP

Published Date

  • January 2000

Published In

Volume / Issue

  • 22 / 1

Start / End Page

  • 41 - 44

PubMed ID

  • 10695820

Pubmed Central ID

  • 10695820

International Standard Serial Number (ISSN)

  • 1077-4114

Digital Object Identifier (DOI)

  • 10.1097/00043426-200001000-00008


  • eng

Conference Location

  • United States